Use of a claims database to characterize and estimate the incidence rate for Castleman disease

被引:145
作者
Munshi, Nikhil [1 ]
Mehra, Maneesha [2 ]
van de Velde, Helgi [3 ]
Desai, Avinash [2 ]
Potluri, Ravi [4 ]
Vermeulen, Jessica [5 ]
机构
[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Janssen Global Serv, Raritan, NJ 08869 USA
[3] Janssen Res & Dev, Beerse, Belgium
[4] SmartAnalyst Inc, New York, NY USA
[5] Janssen Res & Dev, Leiden, Netherlands
关键词
Castleman disease; multicentric Castleman disease; incidence; ANTIBODY; THALIDOMIDE; MANAGEMENT; INFECTION; ANAKINRA; THERAPY; PATIENT;
D O I
10.3109/10428194.2014.953145
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Castleman disease (CD) is a rare lymphoproliferative disorder affecting single (unicentric; UCD) or multiple (multicentric; MCD) lymph nodes. The incidence of this difficult to diagnose disease is poorly understood, as no International Classification of Diseases, Ninth Revision (ICD-9) code is available. This study utilized a unique strategy to estimate its incidence using two commercial claims databases, IMS LifeLink (TM) and Truven Health Analytics MarketScan (R). Patients with an index diagnosis of lymphadenopathy (ICD-9 code 785.6) were followed longitudinally for 1 year prior to and 2 years post-index diagnosis date. An algorithm that identifies potential patients with CD was developed to determine the incidence rate in person-years. The incidence rate for CD was calculated as 21 (IMS LifeLink (TM)) and 25 (MarketScan (R)) per million person-years. Additionally, 23% of patients with CD were identified as potentially suffering from MCD. These results are consistent with the definition of an orphan disease, and the low incidence of the disease estimated in the literature.
引用
收藏
页码:1252 / 1260
页数:9
相关论文
共 45 条
[1]   Cutaneous castleman's disease responds to anti-interleukin-6 treatment [J].
Ahmed, Bilal ;
Tschen, Jaime A. ;
Cohen, Philip R. ;
Zaki, Mohamed H. ;
Rady, Peter L. ;
Tyring, Stephen K. ;
Corringham, Robert E. ;
Kurzrock, Razelle .
MOLECULAR CANCER THERAPEUTICS, 2007, 6 (09) :2386-2390
[2]   Efficacy of bortezomib in refractory form of multicentric Castleman disease associated to poems syndrome (MCD-POEMS variant) [J].
Anna Sobas, Marta ;
Alonso Vence, Natalia ;
Diaz Arias, Jose ;
Bendana Lopez, Angeles ;
Fraga Rodriguez, Maximo ;
Bello Lopez, Jose Luis .
ANNALS OF HEMATOLOGY, 2010, 89 (02) :217-219
[3]  
[Anonymous], 2012, ORPHANET REPORT SERI
[4]   Mixed-type Multicentric Castleman's Disease Developing during a 17-year Follow-up of Sarcoidosis [J].
Awano, Nobuyasu ;
Inomata, Minoru ;
Kondoh, Keisuke ;
Satake, Kohta ;
Kamiya, Hiroyuki ;
Moriya, Atsuko ;
Ando, Tsunehiro ;
Kumasaka, Toshio ;
Takemura, Tamiko ;
Takeuchi, Kengo ;
Ikushima, Soichiro .
INTERNAL MEDICINE, 2012, 51 (21) :3061-3066
[5]   ALLEVIATION OF SYSTEMIC MANIFESTATIONS OF CASTLEMANS DISEASE BY MONOCLONAL ANTI-INTERLEUKIN-6 ANTIBODY [J].
BECK, JT ;
HSU, SM ;
WIJDENES, J ;
BATAILLE, R ;
KLEIN, B ;
VESOLE, D ;
HAYDEN, K ;
JAGANNATH, S ;
BARLOGIE, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (09) :602-605
[6]  
Bowne WB, 1999, CANCER, V85, P706, DOI 10.1002/(SICI)1097-0142(19990201)85:3<706::AID-CNCR21>3.0.CO
[7]  
2-7
[8]   The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care [J].
Casper, C .
BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 (01) :3-17
[9]  
Castleman B, 1954, N Engl J Med, V251, P396
[10]  
Chronowski M, 2001, CANCER, V92, P670